Intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for neoadjuvant treatment of high-risk early breast cancer (GeparOcto-GBG 84): a randomised phase III trial
Background - GeparOcto compared efficacy and safety of two chemotherapy regimens in high-risk early breast cancer (BC): sequential treatment with intense dose-dense epirubicin, paclitaxel, and cyclophosphamide (iddEPC) and weekly treatment with paclitaxel plus non-pegylated liposomal doxorubicin (M,...
Saved in:
| Main Author: | |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
2019
|
| In: |
European journal of cancer
Year: 2018, Volume: 106, Pages: 181-192 |
| ISSN: | 1879-0852 |
| DOI: | 10.1016/j.ejca.2018.10.015 |
| Online Access: | Verlag, Volltext: https://doi.org/10.1016/j.ejca.2018.10.015 Verlag, Volltext: http://www.sciencedirect.com/science/article/pii/S0959804918314564 
|
| Author Notes: | Andreas Schneeweiss, Volker Möbus, Hans Tesch, Claus Hanusch, Carsten Denkert, Kristina Lübbe, Jens Huober, Peter Klare, Sherko Kümmel, Michael Untch, Karin Kast, Christian Jackisch, Jörg Thomalla, Barbara Ingold-Heppner, Jens-Uwe Blohmer, Mahdi Rezai, Matthias Frank, Knut Engels, Kerstin Rhiem, Peter Andreas Fasching, Valentina Nekljudova, Gunter von Minckwitz, Sibylle Loibl |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1669953343 | ||
| 003 | DE-627 | ||
| 005 | 20251025154735.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 190724r20192018xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ejca.2018.10.015 |2 doi | |
| 035 | |a (DE-627)1669953343 | ||
| 035 | |a (DE-599)KXP1669953343 | ||
| 035 | |a (OCoLC)1341234732 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Schneeweiss, Andreas |d 1961- |e VerfasserIn |0 (DE-588)109972554 |0 (DE-627)632849630 |0 (DE-576)327251859 |4 aut | |
| 245 | 1 | 0 | |a Intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for neoadjuvant treatment of high-risk early breast cancer (GeparOcto-GBG 84) |b a randomised phase III trial |c Andreas Schneeweiss, Volker Möbus, Hans Tesch, Claus Hanusch, Carsten Denkert, Kristina Lübbe, Jens Huober, Peter Klare, Sherko Kümmel, Michael Untch, Karin Kast, Christian Jackisch, Jörg Thomalla, Barbara Ingold-Heppner, Jens-Uwe Blohmer, Mahdi Rezai, Matthias Frank, Knut Engels, Kerstin Rhiem, Peter Andreas Fasching, Valentina Nekljudova, Gunter von Minckwitz, Sibylle Loibl |
| 264 | 1 | |c 2019 | |
| 300 | |a 12 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Available online 5 December 2018 | ||
| 500 | |a Gesehen am 24.07.2019 | ||
| 520 | |a Background - GeparOcto compared efficacy and safety of two chemotherapy regimens in high-risk early breast cancer (BC): sequential treatment with intense dose-dense epirubicin, paclitaxel, and cyclophosphamide (iddEPC) and weekly treatment with paclitaxel plus non-pegylated liposomal doxorubicin (M, Myocet®) with additional carboplatin (PM(Cb)) in triple-negative BC (TNBC). - Patients and methods - Patients with cT1c-cT4a-d and centrally assessed human epidermal growth factor receptor (HER)2-positive BC or TNBC were eligible, irrespective of nodal status, luminal B-like tumours only if pN+. Patients were randomised (stratified by BC subtype, Ki67, lymphocyte-predominant BC) to receive 18 weeks of E (150 mg/m2) followed by P (225 mg/m2) followed by C (2000 mg/m2), each q2w for 3 cycles or weekly P (80 mg/m2) plus M (20 mg/m2) plus, in TNBC, Cb (area under curve (AUC) 1.5). HER2-positive BC patients additionally received trastuzumab (6 [loading dose 8]mg/kg q3w) and pertuzumab (420 [840]mg q3w) with all P and C cycles. Primary end-point was pathological complete response (pCR, ypT0/is ypN0), secondary end-points included other pCR definitions, pCR in stratified subpopulations, tolerability and compliance. This trial is registered with ClinicalTrials.gov number NCT02125344. - Results - 945/961 randomised patients started treatment. The median age was 48 years; 7.6% had cT3-4, 46% cN+, 66% G3, 40% HER2-positive, 43% TNBC. pCR rate with iddEPC was 48.3%, with PM(Cb) 48.0%, respectively (PM(Cb) versus iddEPC odds ratio 0.99; 95% confidence interval 0.77-1.28, P = 0.979) with no significant differences observed in TNBC, HER2-positive, luminal B-like subtypes. 16.4% with iddEPC and 34.1% with PM(Cb) discontinued treatment (P < 0.001), mainly due to adverse events; two patients on PM(Cb) died. - Conclusions - In high-risk early BC there is no difference in pCR rates following neoadjuvant treatment with iddEPC or weekly PM(Cb), respectively. iddEPC is one of the effective dose-dense regimens feasible in daily practice. | ||
| 534 | |c 2018 | ||
| 650 | 4 | |a Carboplatin | |
| 650 | 4 | |a Dose-dense | |
| 650 | 4 | |a High-risk early breast cancer | |
| 650 | 4 | |a Neoadjuvant | |
| 773 | 0 | 8 | |i Enthalten in |t European journal of cancer |d Amsterdam [u.a.] : Elsevier, 1992 |g 106(2019), Seite 181-192 |w (DE-627)266883400 |w (DE-600)1468190-0 |w (DE-576)090954173 |x 1879-0852 |7 nnas |a Intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for neoadjuvant treatment of high-risk early breast cancer (GeparOcto-GBG 84) a randomised phase III trial |
| 773 | 1 | 8 | |g volume:106 |g year:2019 |g pages:181-192 |g extent:12 |a Intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for neoadjuvant treatment of high-risk early breast cancer (GeparOcto-GBG 84) a randomised phase III trial |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.ejca.2018.10.015 |x Verlag |x Resolving-System |3 Volltext |
| 856 | 4 | 0 | |u http://www.sciencedirect.com/science/article/pii/S0959804918314564 |x Verlag |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20190724 | ||
| 993 | |a Article | ||
| 994 | |a 2019 | ||
| 998 | |g 109972554 |a Schneeweiss, Andreas |m 109972554:Schneeweiss, Andreas |d 910000 |d 910400 |e 910000PS109972554 |e 910400PS109972554 |k 0/910000/ |k 1/910000/910400/ |p 1 |x j | ||
| 999 | |a KXP-PPN1669953343 |e 3496544449 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"recId":"1669953343","name":{"displayForm":["Andreas Schneeweiss, Volker Möbus, Hans Tesch, Claus Hanusch, Carsten Denkert, Kristina Lübbe, Jens Huober, Peter Klare, Sherko Kümmel, Michael Untch, Karin Kast, Christian Jackisch, Jörg Thomalla, Barbara Ingold-Heppner, Jens-Uwe Blohmer, Mahdi Rezai, Matthias Frank, Knut Engels, Kerstin Rhiem, Peter Andreas Fasching, Valentina Nekljudova, Gunter von Minckwitz, Sibylle Loibl"]},"origin":[{"dateIssuedDisp":"2019","dateIssuedKey":"2019"}],"id":{"eki":["1669953343"],"doi":["10.1016/j.ejca.2018.10.015"]},"language":["eng"],"physDesc":[{"extent":"12 S."}],"type":{"bibl":"article-journal","media":"Online-Ressource"},"title":[{"title_sort":"Intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for neoadjuvant treatment of high-risk early breast cancer (GeparOcto-GBG 84)","title":"Intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for neoadjuvant treatment of high-risk early breast cancer (GeparOcto-GBG 84)","subtitle":"a randomised phase III trial"}],"person":[{"role":"aut","given":"Andreas","family":"Schneeweiss","display":"Schneeweiss, Andreas"}],"relHost":[{"id":{"zdb":["1468190-0"],"issn":["1879-0852"],"eki":["266883400"]},"origin":[{"dateIssuedDisp":"1992-","publisher":"Elsevier ; Pergamon Press","dateIssuedKey":"1992","publisherPlace":"Amsterdam [u.a.] ; [Erscheinungsort nicht ermittelbar]"}],"part":{"year":"2019","pages":"181-192","volume":"106","extent":"12","text":"106(2019), Seite 181-192"},"recId":"266883400","disp":"Intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for neoadjuvant treatment of high-risk early breast cancer (GeparOcto-GBG 84) a randomised phase III trialEuropean journal of cancer","title":[{"title_sort":"European journal of cancer","title":"European journal of cancer"}],"corporate":[{"role":"isb","display":"European Organization for Research on Treatment of Cancer"},{"display":"European Association for Cancer Research","role":"isb"},{"role":"isb","display":"European School of Oncology"}],"type":{"media":"Online-Ressource","bibl":"periodical"},"note":["Gesehen am 21.03.24","Ungezählte Beil.: Supplement"],"titleAlt":[{"title":"EJC online"}],"language":["eng"],"pubHistory":["28.1992 -"]}],"note":["Available online 5 December 2018","Gesehen am 24.07.2019"]} | ||
| SRT | |a SCHNEEWEISINTENSEDOS2019 | ||